As idiosyncratic hepatotoxicity is a concern in ADPKD patients treated with tolvaptan (Blair, 2019), we also examined protein expression of several markers in liver homogenates from the conditional Pkd1 knockout mice to analyze the effects of treatment with vehicle control, BA (30 mg/kg/d) in the presence or absence of high-dose tolvaptan (100 mg/kg/d; Figure 9). Here, PKD1 is linked to autosomal dominant polycystic kidney disease.